DURECT Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de DURECT de 29% y 47.1% respectivamente, mientras que el BPA crecerá en un 29.3% al año.

Información clave

29.0%

Tasa de crecimiento de los beneficios

29.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	22.8%
Tasa de crecimiento de los ingresos	47.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	01 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 10

Recent updates

Brokers Are Upgrading Their Views On DURECT Corporation (NASDAQ:DRRX) With These New Forecasts

Aug 08

DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 10

Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?

Jan 08

Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Aug 05

Durect (DRRX) Investor Presentation - Slideshow

May 06

Durect EPS misses by $0.01, misses on revenue

May 04

DURECT prices ~$43M stock offering

Feb 04

DURECT surges after FDA approval for Posimir

Feb 02

Durect's DUR-928 fast track'd for alcoholic hepatitis in the U.S.

Dec 16

DURECT (DRRX) Investor Presentation - Slideshow

Oct 31

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:DRRX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	24	-43	N/A	N/A	1
12/31/2025	18	-38	N/A	N/A	1
12/31/2024	11	-37	N/A	N/A	3
12/31/2023	9	-28	-34	-34	N/A
9/30/2023	9	-37	-35	-34	N/A
6/30/2023	19	-36	-29	-29	N/A
3/31/2023	19	-36	-30	-30	N/A
12/31/2022	19	-35	-26	-26	N/A
9/30/2022	23	-32	-29	-29	N/A
6/30/2022	13	-39	-34	-34	N/A
3/31/2022	14	-37	-32	-32	N/A
12/31/2021	14	-36	-38	-37	N/A
9/30/2021	9	-38	-35	-35	N/A
6/30/2021	9	-37	-36	-36	N/A
3/31/2021	31	-14	-37	-37	N/A
12/31/2020	30	-14	-39	-39	N/A
9/30/2020	34	-11	-27	-26	N/A
6/30/2020	43	-3	1	1	N/A
3/31/2020	23	-24	4	4	N/A
12/31/2019	25	-21	11	11	N/A
9/30/2019	23	-24	1	1	N/A
6/30/2019	20	-24	-19	-19	N/A
3/31/2019	19	-24	-19	-19	N/A
12/31/2018	15	-25	-20	-20	N/A
9/30/2018	34	-10	-21	-21	N/A
6/30/2018	35	-1	-17	-17	N/A
3/31/2018	36	-4	1	1	N/A
12/31/2017	37	-4	-1	-1	N/A
9/30/2017	21	-21	N/A	-1	N/A
6/30/2017	16	-36	N/A	-10	N/A
3/31/2017	15	-35	N/A	-30	N/A
12/31/2016	14	-35	N/A	-27	N/A
9/30/2016	16	-32	N/A	-26	N/A
6/30/2016	17	-29	N/A	-25	N/A
3/31/2016	18	-26	N/A	-22	N/A
12/31/2015	19	-23	N/A	-21	N/A
9/30/2015	18	-23	N/A	-17	N/A
6/30/2015	18	-23	N/A	-17	N/A
3/31/2015	18	-23	N/A	-17	N/A
12/31/2014	19	-22	N/A	-15	N/A
9/30/2014	19	-21	N/A	-15	N/A
6/30/2014	18	-20	N/A	-15	N/A
3/31/2014	17	-20	N/A	-15	N/A
12/31/2013	15	-21	N/A	-15	N/A
9/30/2013	14	-22	N/A	-15	N/A
6/30/2013	15	-21	N/A	-14	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que DRRX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que DRRX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que DRRX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (47.1% al año) de DRRX crezcan más rápidamente que los del mercado US (7.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (47.1% al año) de DRRX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de DRRX se prevé que sea elevada dentro de 3 años.

DURECT Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased to US$5.33

Consensus revenue estimates fall by 16%

No longer forecast to breakeven

DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Forecast to breakeven in 2024

Price target decreased to US$6.50

Recent updates

DURECT Corporation to Report Q4, 2023 Results on Mar 27, 2024

DURECT Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

DURECT Corporation to Report Q3, 2023 Results on Nov 13, 2023

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

Durect Corporation Announces Last Patient Last Visit in Phase 2B Ahfirm Trial of Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation to Report Q2, 2023 Results on Aug 09, 2023

DURECT Corporation Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation to Report Q3, 2022 Results on Nov 02, 2022

DURECT Corporation Announces Enrollment of More Than 200 of Planned 300 Patients in is Phase 2b AHFIRM Trial

Innocoll Pharmaceuticals Limited and DURECT Corporation Announce U.S. Launch of POSIMIR

DURECT Corporation Receives Approval from the Listing Qualifications Department of Nasdaq for an Additional 180-Day Grace Period, or Until February 6, 2023

Brokers Are Upgrading Their Views On DURECT Corporation (NASDAQ:DRRX) With These New Forecasts

Price target decreased to US$5.33

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

DURECT Corporation to Report Q2, 2022 Results on Aug 04, 2022

DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

Durect names ex-RBC Capital Markets executive as CFO

High number of new directors

Is DURECT (NASDAQ:DRRX) A Risky Investment?

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new directors

DURECT Corporation, Annual General Meeting, Jun 15, 2022

Independent Director recently bought US$118k worth of stock

Consensus revenue estimates fall by 16%

DURECT Corporation (NASDAQ:DRRX) Analysts Are More Bearish Than They Used To Be

No longer forecast to breakeven

DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

DURECT Corporation Announces Resignation of Michael Arenberg as Chief Financial Officer, Effective March 17, 2022

Durect Corporation Doses First European Patient in Phase 2B Ahfirm Study of Larsucosterol(Dur-928) in Severe Alcohol-Associated Hepatitis

DURECT Corporation to Report Q4, 2021 Results on Mar 07, 2022

Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?

High number of new directors

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.044 loss per share (vs US$0.046 loss in 3Q 2020)

Price target decreased to US$6.50

Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.073 profit in 2Q 2020)

Price target increased to US$7.25

Forecast to breakeven in 2024

DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021

DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH and in Hepatic Impairment At Upcoming International Liver Conference 2021

Durect (DRRX) Investor Presentation - Slideshow

Durect EPS misses by $0.01, misses on revenue

Durect Corporation Announces Publication of Dur-928'S Mechanism of Action

DURECT Corporation to Report Q4, 2020 Results on Mar 04, 2021

DURECT prices ~$43M stock offering

DURECT Corporation Announces U.S. FDA Approval of POSIMIR® for Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression

DURECT surges after FDA approval for Posimir

DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis

DURECT Corporation Announces Board Changes

DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million

DURECT Corporation Announces Dur-928 Granted Fda Fast Track Designation for Treatment of Alcoholic Hepatitis

Durect's DUR-928 fast track'd for alcoholic hepatitis in the U.S.

DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience 2020

DURECT Corporation Appoints Norman Sussman as Chief Medical Officer

DURECT Corporation Appoints Norman Sussman as Chief Medical Officer

DURECT (DRRX) Investor Presentation - Slideshow

DURECT Corporation to Report Q3, 2020 Results on Nov 02, 2020

DURECT Corporation to Present Additional Safety and Efficacy Signals from Phase 1B Clinical Trial of Dur-928 in Nash Patients At the Liver Meeting Digital Experience 2020

DURECT Corporation Announces First Patient Dosed in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury

Durect Corporation Announces the Study Design for the Phase 2B Ahfirm Clinical Trial of DUR-928 in Severe Alcoholic Hepatitis (AH) Patients

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento